{"TopicDetails": {"type": 0, "ccm2Id": 46873013, "cftId": 0, "identifier": "EU4H-2023-PJ-2-1", "title": "Call for proposals: action grants on the safety and quality of new Substances of Human Origin (Breast milk, faecal microbiota transplants) (b) HS-g-23-50.02 Faecal microbiotic transplants (HS-g-23-50.02)", "publicationDateLong": 1712620800000, "callIdentifier": "EU4H-2023-PJ-2", "callTitle": "Call for proposals: action grants on the safety and quality of new Substances of Human Origin (Breast milk, faecal microbiota transplants) (b) HS-g-23-50.02 Faecal microbiotic transplants (HS-g-23-50.02)", "callccm2Id": 46873067, "allowPartnerSearch": true, "frameworkProgramme": {"id": 43332642, "abbreviation": "EU4H", "description": "EU4 Health Programme (EU4H)"}, "programmeDivision": [{"id": 43332657, "abbreviation": "Health", "description": "Improving and fostering health in the Union to reduce the burden of communicable and non-communicable diseases"}, {"id": 43332653, "abbreviation": "EU4H-1", "description": "EU4H-1"}], "topicMGAs": [], "tags": ["HS-g-23-50.02"], "sme": false, "actions": [{"status": {"id": 31094503, "abbreviation": "Closed", "description": "Closed"}, "types": [{"typeOfAction": "EU4H-PJG EU4H Project Grants", "typeOfMGA": [{"id": 43326018, "abbreviation": "EU4H-AG", "description": "EU4H Action Grant Budget-Based"}]}], "plannedOpeningDate": "09 April 2024", "submissionProcedure": {"id": 31094504, "abbreviation": "single-stage", "description": "single-stage"}, "deadlineDates": ["11 June 2024"]}], "latestInfos": [{"approvalDate": "Jun 25, 2024 10:45:22 AM", "lastChangeDate": "Jun 25, 2024 10:45:22 AM", "content": "<p>Call&nbsp;<span style=\"color: rgb(51, 51, 51); font-family: eui-light, &quot;Helvetica Neue&quot;, Helvetica, sans-serif; font-size: 16px;\">EU4H-2023-PJ-2-1</span>&nbsp;<span style=\"color: rgb(64, 64, 64); font-family: Arial, &quot;Helvetica Neue&quot;, Helvetica, sans-serif; font-size: 16px;\">has closed on</span><span style=\"color: rgb(64, 64, 64); font-family: Arial, &quot;Helvetica Neue&quot;, Helvetica, sans-serif; font-size: 16px;\">&nbsp;</span><span style=\"color: rgb(64, 64, 64); font-family: Arial, &quot;Helvetica Neue&quot;, Helvetica, sans-serif; font-size: 16px; box-sizing: inherit; font-weight: 700;\">11 June 2024.</span></p>\r\n<p style=\"box-sizing: inherit; font-size: 16px; line-height: 1.4; color: rgb(64, 64, 64); font-family: Arial, &quot;Helvetica Neue&quot;, Helvetica, sans-serif;\"><span style=\"box-sizing: inherit; font-weight: 700;\">3&nbsp;</span>proposals have been submitted.</p>\r\n<p style=\"box-sizing: inherit; font-size: 16px; line-height: 1.4; color: rgb(64, 64, 64); font-family: Arial, &quot;Helvetica Neue&quot;, Helvetica, sans-serif;\">Evaluation results are expected to be communicated in&nbsp;<span style=\"box-sizing: inherit; font-weight: 700;\">July 2024.</span></p>"}], "budgetOverviewJSONItem": {"budgetTopicActionMap": {"3531700": [{"action": "EU4H-2023-PJ-2-1 - EU4H-PJG EU4H Project Grants", "plannedOpeningDate": "09 April 2024", "deadlineModel": "single-stage", "deadlineDates": ["11 June 2024"], "budgetYearMap": {"2023": 400000}, "budgetTopicActionMap": {}}]}, "budgetYearsColumns": ["2023"]}, "description": "<SPAN class=\"topicdescriptionkind\">ExpectedOutcome</SPAN>:<p><strong>Policy Context</strong></p><p>The 2019 evaluation of the Union legislation on blood, tissues and cells identified a legal gap in terms of Regulation for some therapies made from substances of human origin (SoHO) that cannot necessarily be defined as blood, tissues, cells or organs. It concerns in particular therapies like human faecal microbiota transplants (FMT) and breast milk (BM), whose use entails the need to avoid transmission of diseases from donors. The revision of the Union legislative frameworks (blood and tissues and cells) aims to cover this gap and it plans to address safety and quality requirements for these therapies.</p><p>Dedicated guidelines on safety and quality have also to be implemented by a new group of actors with expertise on these therapies. It is estimated that around 200 new entities or establishments, working with BM or FMT, will be regulated under the new SoHO legislation. This action will help actors and establishments for the preparation of the implementation of these new legal requirements.</p><p>This action implements the EU4Health Programme\u2019s general objective of improving the availability, accessibility and affordability of medicinal products and medical devices, and crisis-relevant products in the Union, and supporting innovation regarding such products (Article 3, point (c) of Regulation (EU) 2021/522) through the specific objectives defined in Article 4, points (c) and (h), of Regulation (EU) 2021/522.</p>\n<SPAN class=\"topicdescriptionkind\">Objective</SPAN>:<p><strong>Objectives, scope and activities</strong></p><p>This action aims to bring together sector professionals, for BM (subtopic (a)) and for FMT (subtopic (b)), and to facilitate the implementation of new SoHO guidelines and legislative requirements as well as the compliance with oversight tasks, in order to allow thesafe, effective and qualitative use of these SoHO-based therapies.</p><p>The activities for both subtopics (a) and (b) are:</p><p>a) building an expert forum on breast milk and an expert forum on faecal microbiota transplants;</p><p>b) developing, for each SoHO-based therapy, a common set of draft guidelines on the basis of the expert forum and existing initiatives (e.g. professional societies\u2019 work, work in research actions);</p><p>c) possible future updating of the guidelines, taking account of the new EU legislative framework;</p><p>d) providing an implementation plan for establishments/entities in order to implement SoHO requirements, which will also consider the compliance with technical guidelines as well as with oversight provisions (entity and establishment authorisations, preparation process authorisations, inspections, vigilance and traceability); and</p><p>e) training and dissemination programme.</p><p>These activities are to be developed taking account the commonalities and specificities of both SoHO-based therapies, i.e. BM and FMT.</p>\n<SPAN class=\"topicdescriptionkind\">Expected Impact</SPAN>:<p><strong>Expected results and impact</strong></p><p>The two sub-topics should provide up-to-date guidelines on:</p><p>a) technical safety and quality aspects for BM (subtopic (a)) and for FMT (subtopic (b));</p><p>b) implementation of the legal requirements by establishments preparing these substances covered by both subtopics and applying therapies based on them.</p><p>They will also create a forum where key experts including Member States authorities can be engaged also in the future whenever the guidelines need to be updated, or when further advice is needed on their implementation.</p><p>Both subtopics will support the implementation of the new Union legislative framework on SoHO.</p><p>The result of the subtopic on faecal microbiota will consider the coherence with pharmaceutical actors/legislation, so that actors from both sectors (SoHO and Pharmaceuticals) can look into technical rules for faecal microbiota collected under SOHO and later to be used for manufacturing of pharmaceuticals.</p>\n", "conditions": "<p><b><span lang=\"EN-US\" style=\"font-size: 12pt; line-height: 18.4px; color: rgb(64, 64, 64);\">Conditions<br />\r\n<br type=\"_moz\" />\r\n</span></b></p>\r\n<p><b><span lang=\"EN-US\" style=\"color:#404040;mso-themecolor:&#10;text1;mso-themetint:191;mso-ansi-language:EN-US\">1.&nbsp;</span></b><b><span lang=\"EN-US\">Admissibility conditions: </span></b><span lang=\"EN-US\">described in section 5 of the call document</span>&nbsp;</p>\n<p><b><span lang=\"EN-US\">Proposal page limits and layout:</span></b><span lang=\"EN-US\">&nbsp;described in Part B of the Application Form available in the Submission System</span></p>\n<p><b><span lang=\"EN-US\">2. Eligible countries:&nbsp;</span></b><span lang=\"EN-US\">described in section 6 of of the call document</span></p>\n<p><b><span lang=\"EN-US\">3. Other eligibility conditions:</span></b><span lang=\"EN-US\">&nbsp;described in section 6 of the call document</span></p>\n<p><b>4. Financial and operational capacity and exclusion:&nbsp;</b>described in&nbsp;<span lang=\"EN-US\">section 7 of the call document</span></p>\n<p><b><span lang=\"FR-BE\">5.&nbsp;Evaluation and award:</span></b></p>\n<ul>\r\n    <li><b><span lang=\"EN-US\">Award criteria, scoring and thresholds:</span></b><span lang=\"EN-US\">&nbsp;described in section 9 of the call document</span></li>\r\n</ul>\n<ul>\r\n    <li><b><span lang=\"EN-US\" style=\"color: rgb(64, 64, 64);\">Submission and evaluation processes</span></b><b><span lang=\"EN-US\">:</span></b><span lang=\"EN-US\">&nbsp;described&nbsp;<span style=\"color: rgb(64, 64, 64);\">section 8 of the call document and the</span>&nbsp;</span><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/om_en.pdf\"><span lang=\"EN-US\">Online Manual</span></a></li>\r\n</ul>\n<ul>\r\n    <li><b><span lang=\"EN-US\">Indicative timeline for evaluation and grant agreement:&nbsp;</span></b><span lang=\"EN-US\">described in section 4 of the call document</span></li>\r\n</ul>\n<p><b><span lang=\"EN-US\" style=\"color: rgb(64, 64, 64);\">6</span></b><b><span lang=\"EN-US\">. Legal and financial set-up of the grants:&nbsp;</span></b><span lang=\"EN-US\">described&nbsp;<span style=\"color: rgb(64, 64, 64);\">in section 10 of the call document</span></span></p>\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><b><span lang=\"EN-US\" style=\"font-size: 12pt; line-height: 18.4px; color: rgb(64, 64, 64);\">Documents<br />\r\n<br />\r\n<o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span lang=\"EN-US\" style=\"color:#404040;mso-themecolor:text1;mso-themetint:191;&#10;mso-ansi-language:EN-US\"><b><span lang=\"EN-US\">Call documents:</span></b></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span lang=\"EN-US\" style=\"color:#404040;mso-themecolor:text1;mso-themetint:191;&#10;mso-ansi-language:EN-US\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/eu4h/wp-call/2023/call-fiche_eu4h-2023-pj-2_en.pdf\" target=\"_blank\">Call document </a><o:p></o:p></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span lang=\"EN-US\" style=\"color:#404040;mso-themecolor:text1;mso-themetint:191;mso-ansi-language:&#10;EN-US\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/eu4h/temp-form/af/af_eu4h_en.pdf\" target=\"_blank\">Standard application form ([ToA])</a>&nbsp;</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span lang=\"EN-US\" style=\"color:#404040;mso-themecolor:text1;mso-themetint:191;&#10;mso-ansi-language:EN-US\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/eu4h/temp-form/af/detailed-budget-table_eu4h_en.xlsm\" target=\"_blank\">Detailed budget table ([ToA])</a><o:p></o:p></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:4.0pt;line-height:normal;tab-stops:&#10;191.4pt\"><span style=\"color:#404040;mso-themecolor:text1;mso-themetint:&#10;191;mso-fareast-language:EN-GB;mso-no-proof:yes\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/eu4h/agr-contr/mga_eu4h_en.pdf\" target=\"_blank\">EU4Health Programme General MGA v1.1</a><o:p></o:p></span></p>\n<p><span class=\"MsoHyperlink\"><span style=\"color: rgb(64, 64, 64);\"><a href=\"https://health.ec.europa.eu/publications/2024-eu4health-work-programme_en\" target=\"_blank\">EU4Health Work Programme 2024</a></span></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom: 0.0001pt;\"><span lang=\"EN-US\" style=\"color: rgb(64, 64, 64);\"><a href=\"https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32021R0522\" target=\"_blank\"><span lang=\"EN-US\">EU4Health </span></a><span lang=\"EN-US\"><a href=\"https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32021R0522\" target=\"_blank\">Regulation 2021/522</a></span></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom: 0.0001pt;\"><span lang=\"EN-US\" style=\"color: rgb(64, 64, 64);\"><br />\r\n</span><a href=\"https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32018R1046&amp;qid=1535046024012\"><span lang=\"EN-US\">EU Financial Regulation 2018/1046</span></a></p>", "supportInfo": "<p><span style=\"font-family: Arial, sans-serif; font-size: 9pt;\">For help related to this</span><span style=\"font-family: Arial, sans-serif; font-size: 9pt;\">&nbsp;</span><b style=\"font-family: Arial, sans-serif; font-size: 9pt;\">call</b><span style=\"font-family: Arial, sans-serif; font-size: 9pt;\">, please contact:&nbsp;</span><span style=\"font-family: Arial, sans-serif;\"><a href=\"mailto:HaDEA-HP-CALLS@ec.europa.eu\" target=\"_blank\">HaDEA-HP-CALLS@ec.europa.eu</a></span></p>\r\n<p class=\"MsoNormal\" style=\"line-height: normal;\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/faq;grantAndTendertype=1;categories=p_submission_eval;programme=null;actions=;keyword=;period=null\"><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">Funding &amp; Tenders Portal FAQ</span></a><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;&ndash; Submission of proposals.<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\" style=\"line-height: normal;\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/helpdesks/contact-form\"><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">IT Helpdesk</span></a><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;&ndash; Contact the IT helpdesk for questions such as forgotten passwords, access rights and roles, technical aspects of submission of proposals, etc.<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\" style=\"line-height: normal;\"><a href=\"https://webgate.ec.europa.eu/funding-tenders-opportunities/display/OM/Online+Manual\"><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">Online Manual</span></a><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;&ndash; Step-by-step online guide through the Portal processes from proposal preparation and submission to reporting on your on-going project. Valid for all 2021-2027 programmes.</span></p>", "sepTemplate": "<p>To access the Electronic Submission Service, please click on the submission-button next to the <strong>type of action</strong> and the <strong>type of model grant agreement</strong> that corresponds to your proposal. You will then be asked to confirm your choice, as it cannot be changed in the submission system. Upon confirmation, you will be linked to the correct entry point.</p>\r\n<p>To access existing draft proposals for this topic, please login to the Funding &amp; Tenders Portal and select the My Proposals page of the My Area section.</p>", "links": [], "additionalDossiers": [], "infoPackDossiers": [], "callDetailsJSONItem": {"latestInfos": [{"approvalDate": "Jun 25, 2024 10:45:22 AM", "lastChangeDate": "Jun 25, 2024 10:45:22 AM", "content": "<p>&nbsp;Call&nbsp;<span style=\"color: rgb(51, 51, 51); font-family: eui-light, &quot;Helvetica Neue&quot;, Helvetica, sans-serif; font-size: 16px;\">EU4H-2023-PJ-2-1</span>&nbsp;<span style=\"color: rgb(64, 64, 64); font-family: Arial, &quot;Helvetica Neue&quot;, Helvetica, sans-serif; font-size: 16px;\">has closed on</span><span style=\"color: rgb(64, 64, 64); font-family: Arial, &quot;Helvetica Neue&quot;, Helvetica, sans-serif; font-size: 16px;\">&nbsp;</span><span style=\"color: rgb(64, 64, 64); font-family: Arial, &quot;Helvetica Neue&quot;, Helvetica, sans-serif; font-size: 16px; box-sizing: inherit; font-weight: 700;\">11 June 2024.</span></p>\r\n<p style=\"box-sizing: inherit; font-size: 16px; line-height: 1.4; color: rgb(64, 64, 64); font-family: Arial, &quot;Helvetica Neue&quot;, Helvetica, sans-serif;\"><span style=\"box-sizing: inherit; font-weight: 700;\">3&nbsp;</span>proposals have been submitted.</p>\r\n<p style=\"box-sizing: inherit; font-size: 16px; line-height: 1.4; color: rgb(64, 64, 64); font-family: Arial, &quot;Helvetica Neue&quot;, Helvetica, sans-serif;\">Evaluation results are expected to be communicated in&nbsp;<span style=\"box-sizing: inherit; font-weight: 700;\">July 2024.</span></p>"}, {"approvalDate": "Apr 9, 2024 12:00:00 AM", "lastChangeDate": "Apr 9, 2024 12:00:00 AM", "content": "The submission session is now available for: EU4H-2023-PJ-2-1(EU4H-PJG)"}], "hasForthcomingTopics": false, "hasOpenTopics": false, "allClosedTopics": true}}}